Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03186937 · ClinicalTrials.gov registry record · Phase 2
A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03186937 is a Phase 2 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 6 participants.
The verdict
NCT03186937, a Phase 2 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
Given preliminary data demonstrating that methionine deprivation enhances cell surface expression of TRAIL receptor-2, the objective of this clinical trial is to confirm that methionine restriction enhances its expression in triple negative breast cancer and to establish the feasibility and acceptability of this dietary intervention in humans. This study will also examine the effect of methionine restriction on cancer stem cells and metabolic health.
Interventions
- DIETARY_SUPPLEMENT hominex-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-08-10 |
| Est. Completion | 2019-06-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03186937
The ClinicalTrials.gov registry entry for NCT03186937 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which hominex-2 is the first listed.
NCT03186937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03186937 about?
NCT03186937 is a clinical study titled "A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer". Given preliminary data demonstrating that methionine deprivation enhances cell surface expression of TRAIL receptor-2, the objective of this clinical trial is to confirm that methionine restriction enhances its expression in triple negative breast cancer and to establish the feasibility and acceptab...
What is the current status of trial NCT03186937?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2017-08-10. Estimated completion is 2019-06-21.
What interventions are being tested in trial NCT03186937?
The interventions under investigation include: hominex-2 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03186937?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.